Skip to main content

Advertisement

Table 2 Comparisons of clinical features and biochemical parameters between diabetic group and non-diabetic group

From: Correlations of microRNA-124a and microRNA-30d with clinicopathological features of breast cancer patients with type 2 diabetes mellitus

  Diabetic group (n = 72) Non-diabetic group (n = 144) t2 P value
Age (years) 52.72 ± 6.23 50.08 ± 4.76 3.113 <0.001
Family history of BC 5.56% (4) 4.17% (6) 0.458 0.647
Underlying diseases 19.44% (14) 20.83% (30) 0.057 0.811
Ratio of menopause 76.39% (55) 55.56% (80) 8.889 0.003
BMI (Kg/m2) 24.68 ± 4.74 23.21 ± 3.25 2.673 0.008
SBP (mmHg) 124.68 ± 10.35 125.36 ± 11.23 0.430 0.667
DBP (mmHg) 78.36 ± 7.93 80.57 ± 8.54 1.835 0.068
HDL-C (mmol/L) 1.21 ± 0.32 1.31 ± 0.36 1.995 0.047
LDL-C (mmol/L) 3.85 ± 0.74 3.12 ± 0.65 7.425 <0.001
TG (mmol/L) 1.32 ± 0.35 1.41 ± 0.41 1.594 0.112
TC (mmol/L) 4.45 ± 0.87 3.64 ± 0.68 7.498 <0.0001
FPG (mmol/L) 8.32 ± 0.73 5.27 ± 0.43 38.56 <0.001
2hPG (mmol/L) 14.68 ± 1.02 5.58 ± 0.47 89.810 <0.001
HbA1c (%) 10.57 ± 2.11 5.64 ± 1.57 19.320 <0.001
FIns (uU/mL) 10.14 ± 3.25 5.33 ± 1.87 6.954 <0.001
HOMA-IS 42.84 ± 14.53 60.50 ± 16.29 7.779 <0.001
HOMA-IR 3.75 ± 1.25 1.27 ± 0.50 20.750 <0.001
E2 (pg/mL) 50.20 ± 11.40 23.66 ± 8.63 19.080 <0.001
  1. Comparisons on family history of BC, underlying diseases and the ratio of menopause between the two groups were measured by χ2 test; BMI, weight (kg)/height (m2); Normal BMI, 18.5–22.9 kg/m2
  2. Diabetic group, breast cancer patients with type 2 diabetes mellitus; Non-diabetic group, breast cancer patients without type 2 diabetes mellitus
  3. BC breast cancer, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglyceride, TC total cholesterol, FPG fasting blood glucose, 2hPG 2-hour postprandial blood glucose, HbA1c glycosylated hemoglobin, FIns fasting insulin, HOMA-IR homeostasis model assessment of insulin resistance, HOMA-IS HOMA of β-cell insulin secretion, E 2 estradiol